Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Rigosertib for myelodysplastic syndrome - second line Rigosertib (Estybon; ON-01910.Na) Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2020 View  |  Download
Riluzole oral film formulation for amyotrophic lateral sclerosis Riluzole Amyotrophic lateral sclerosis Neurology 2022 View  |  Download
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia Rilzabrutinib Immune thrombocytopenia (ITP) Haematology , Immunology 2023 View  |  Download
Rimegepant for the treatment of Acute Migraine Rimegepant (Zydis; BHV3000; Nurtec) Migraine Neurology 2018 View  |  Download
Ripretinib for gastrointestinal stromal tumour Ripretinib (DCC-2618; Quinlock) Gastrointestinal stromal tumour (GIST) Gastrointestinal Cancer 2021 View  |  Download
Ripretinib for treating advanced gastrointestinal stromal tumours – fourth-line Ripretinib (DCC-2618; Quinlock) Gastrointestinal stromal tumour (GIST) Gastrointestinal Cancer 2020 View  |  Download
Risankizumab (by subcutaneous injection) for Active Psoriatic Arthritis After Inadequate Control or Intolerance to Conventional Drugs Risankizumab (BI 655066; Skyrizi; ABBV 066) Psoriatic arthritis Dermatology , Rheumatology 2017 View  |  Download
Risankizumab (by Subcutaneous Injection) for Moderate to Severe Chronic Plaque Psoriasis Risankizumab (BI 655066; Skyrizi; ABBV 066) Plaque psoriasis Dermatology 2017 View  |  Download
Risankizumab for moderate to severe crohn’s disease Risankizumab (BI 655066; Skyrizi; ABBV 066) Crohn's disease Gastroenterology , Immunology 2021 View  |  Download
Risankizumab for moderate to severe ulcerative colitis Risankizumab (BI 655066; Skyrizi; ABBV 066) Ulcerative colitis Gastroenterology 2022 View  |  Download
1 2 88 89 90 91 92 117 118
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications